| 國立成功大學 |
2023 |
Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis
|
Tseng, C.-H.;Chen, T.-H.;Wu, J.-L.;Lee, T.-Y.;Borghi, J.A.;Lin, J.-T.;Nguyen, M.H.;Hsu, Y.-C. |
| 國立成功大學 |
2023 |
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials
|
Wong, V.W.-S.;Tak, W.Y.;Goh, Goh G.B.B.;Cheng, P.-N.;Lawitz, E.J.;Younossi, Z.M.;Vuppalanchi, R.;Younes, Z.;Alkhouri, N.;Wang, L.;Liu, J.;Kersey, Kersey K.;Myers, R.P.;Harrison, S.A.;Goodman, Z.;Trauner, M.;Romero-Gomez, M.;Anstee, Q.M.;Nguyen, M.H.;Okanoue, T. |
| 臺大學術典藏 |
2022-09-09T04:21:24Z |
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
|
Park J.; Le A.K.; Tseng T.-C.; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO; Yang H.-I.; Nguyen M.H. |
| 臺大學術典藏 |
2022-09-09T04:21:20Z |
Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities
|
Hsu Y.-C.; Tseng C.-H.; Su T.-H.; JIA-HORNG KAO; Nguyen M.H. |
| 臺大學術典藏 |
2022-09-07T06:39:27Z |
Fluconazole versus an echinocandin for Candida glabrata fungaemia: A retrospective cohort study
|
Eschenauer G.A.; Carver P.L.; SHU-WEN LIN; Klinker K.P.; Chen Y.-C.; Potoski B.A.; Shields R.K.; Clancy C.J.; Nguyen M.-H.; Lam S.W. |
| 臺大學術典藏 |
2022-02-23T02:12:18Z |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu Y.-C.; Yeh M.-L.; Wong G.L.-H.; CHIEN-HUNG CHEN; Peng C.-Y.; Buti M.; Enomoto M.; Xie Q.; Trinh H.; Preda C.; Liu L.; Cheung K.-S.; Yeo Y.H.; Hoang J.; Huang C.-F.; Riveiro-Barciela M.; Kozuka R.; Istratescu D.; Tsai P.-C.; Accarino E.V.; Lee D.-H.; Wu J.-L.; Huang J.F.; Dai C.-Y.; Cheung R.; Chuang W.-L.; Yuen M.-F.; Wong V.W.-S.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
|
Hsu Y.-C.; Yeh M.-L.; Wong G.L.-H.; CHIEN-HUNG CHEN; Peng C.-Y.; Buti M.; Enomoto M.; Xie Q.; Trinh H.; Preda C.; Liu L.; Cheung K.-S.; Yeo Y.H.; Hoang J.; Huang C.-F.; Riveiro-Barciela M.; Kozuka R.; Istratescu D.; Tsai P.-C.; Accarino E.V.; Lee D.-H.; Wu J.-L.; Huang J.F.; Dai C.-Y.; Cheung R.; Chuang W.-L.; Yuen M.-F.; Wong V.W.-S.; Yu M.-L.; Nguyen M.H. |
| 臺大學術典藏 |
2022-02-18T08:26:01Z |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
|
Hsu Y.-C.; Nguyen M.H.; Mo L.-R.; Wu M.-S.; Yang T.-H.; CHIEH-CHANG CHEN; Tseng C.-H.; Tai C.-M.; Wu C.-Y.; Lin J.-T.; Tanaka Y.; Chang C.-Y. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; CHUN-JEN LIU; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 國立成功大學 |
2022 |
Reply
|
Hsu, Y.-C.;Wu, J.-L.;Nguyen, M.H. |
